Celera Genomics Corp.

45 W. Gude Dr.

Year founded: 1998

Industry: Biotechnology

Post 200 Category: Top 125 Companies

Revenue: $60.13 Million

Net Income/Loss: ($57,476,000.00)

Earnings per share: ($0.79)

Dividend: n/a

Stockholder equity: $937.43 Million

Auditor: PricewaterhouseCoopers LLP

Stock: CRA

Assets: $1.02 Billion

Market capitalization: $749.00 Million

52-week high: 14.73 12/2/2004

52-week low: 9.55 4/5/2005

President: Kathy P. Ordoņez

Chief scientific officer: Robert Booth

Employees: 484

Local employees: 300

Description: Celera is a biotechnology company that uses genetic information to develop new medical tests and treatments. The company is a wholly owned subsidiary of Applera of Norwalk, Conn., but it is represented by a separate tracking stock traded on the New York Stock Exchange under the symbol CRA.

Developments: Celera continued its transformation from a genetic database company, with the brash J. Craig Venter in charge, to a drug development company, with low-key President Kathy Ordonez guiding it. Ordonez signed three deals with pharmaceutical and biotech companies designed to capitalize on Celera's possible therapeutic discoveries while limiting financial risks and expenses during the costly development process. A deal with leading biotech firm Genentech calls for the San Francisco company to develop drugs using certain proteins that Celera has linked to cancer, then pay royalties at key stages in the development process. Celera also signed deals to provide cancer therapy targets to Abbott Laboratories and Seattle Genetics. The memory of Celera's days as the pioneering mapper of the human genome remain primarily in the $700 million in cash on its balance sheet to fund discovery of more potential drug discoveries.